Table 2.
Baseline patient characteristics–adenocarcinoma/undifferentiated histology cohort.
| carboplatin + paclitaxel | cisplatin + capecitabine | |||
|---|---|---|---|---|
| Number randomised | 6 | 5 | ||
| Median age (years), IQR | 73.8, 70.1–76.3 | 71.4, 60.3–72.0 | ||
| Gender | ||||
| Male | 5 | (83.3) | 4 | (80.0) |
| Female | 1 | (16.7) | 1 | (20.0) |
| WHO performance status | ||||
| 0 | 4 | (66.7) | 3 | (60.0) |
| 1 | 2 | (33.3) | 2 | (40.0) |
| Reason for non-surgical therapy | ||||
| Clinician's choice | 1 | (16.7) | 1 | (20.0) |
| Co-morbidity/Poor performance status | 2 | (33.3) | 1 | (20.0) |
| Local extent of disease | 2 | (33.3) | 1 | (20.0) |
| Patient choice | 1 | (16.7) | 2 | (40.0) |
| T - Stage | ||||
| T1 | 0 | (0.0) | 1 | (20.0) |
| T2 | 1 | (16.7) | 0 | (0.0) |
| T3 | 4 | (66.7) | 3 | (60.0) |
| T4a | 1 | (16.7) | 1 | (20.0) |
| N - stage | ||||
| N0 | 1 | (16.7) | 3 | (60.0) |
| N1 | 4 | (66.7) | 0 | (0.0) |
| N2 | 1 | (16.7) | 2 | (40.0) |
| Histologic grade | ||||
| G1 | 1 | (16.7) | 0 | (0.0) |
| G2 | 4 | (66.7) | 3 | (60.0) |
| G3 | 1 | (16.7) | 1 | (20.0) |
| Screening TNM v7 Stage | ||||
| I | 0 | (0.0) | 1 | (20.0) |
| IIb | 2 | (33.3) | 2 | (40.0) |
| III | 4 | (66.7) | 2 | (40.0) |
| Site of predominant tumour | ||||
| Mid-point (24 to <32 cm) | 2 | (33.3) | 1 | (20.0) |
| Lower 1/3 (32–40 cm) | 4 | (66.7) | 4 | (80.0) |
| Median overall length of primary tumour (cm), IQR | 4.9, 3.0–6.0 | 4, 3.7–7.0 | ||
| Total disease length (cm), IQR | 5.7, 4.0–7.4 | 4.5, 4.0–5.0 | ||
| Baseline SUVmax– median IQR | 8.9 (7.5–10.6) | 8.5 (7.6–8.7) | ||
| % change in SUVmaxto day 14 - median IQRa | 7.9 (−8.0-25.5) | 7.1 (−5.3-20.3) | ||
NB. n (%) unless otherwise specified.
a
100 × (SUVmax at 14 days/SUVmax at baseline).